Evotec (EVT) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
5 Nov, 2026Executive summary
Q3 revenue was broadly stable YoY and adjusted EBITDA improved to near break-even; 9M revenue declined, while D&PD base-business net sales rose 24%.
FY 2026 guidance was reaffirmed, with revenue and adjusted EBITDA expected toward the upper ends of their ranges.
The 2030 framework targets ~€1bn revenue and an adjusted EBITDA margin above 20%.
Financial highlights
Q3 group revenue was €164.9m, up 0.6% YoY; at constant exchange rates it was €164.2m versus €163.9m.
9M group revenue was €465.0m, down 13.1% reported and 10.8% at constant exchange rates; base revenue fell 12.4% to €441.1m.
Q3 adjusted group EBITDA loss narrowed to €1.6m from €15.0m; the 9M loss widened to €44.3m from €16.9m, or €39.1m at constant exchange rates.
9M gross profit was €16.6m and gross margin 3.6%, versus €57.1m and 10.7% a year earlier.
9M operating loss was €254.8m and net loss €195.3m; reorganization costs were €91.9m and included a €42.3m Hamburg laboratory impairment.
Outlook and guidance
FY 2026 guidance remains €570m–€610m revenue reported (€595m–€635m at constant FX) and an adjusted EBITDA loss of €70m–€105m (€60m–€90m at constant FX); both are expected toward the upper ends.
Horizon targets ~€75m annual run-rate savings by end-2027; more than 20% had been delivered by September, with 20%–30% planned for 2026.
The 2028 mid-range plan targets a 20% adjusted EBITDA margin; 2030 targets ~€1bn revenue and an adjusted EBITDA margin above 20%.
2030 revenue mix targets are 40% D&PD base business, 20% strategic partnerships and 40% JEB.
Latest events from Evotec
- Horizon transformation and scientific expertise drive growth, with licensing and partnerships boosting margins.EVT
Morgan Stanley 24th Annual Global Healthcare Conference - Revenue and profitability declined sharply, with losses deepening and guidance lowered for 2026.EVT
Q2 2026 - Accelerating growth with innovation, cost savings, and a high-value asset pipeline.EVT
Company presentation - 2026 outlook cut as partnership delays weigh, but core business segments show strong momentum.EVT
Q2 2026 TU - Annual meeting to elect Trustees, review governance, and address audit and risk oversight.EVT
Proxy filing - Biologics growth, cost savings, and Horizon transformation drive high-end 2025 results.EVT
Q4 2025 - Biologics growth and €40m cost savings offset R&D decline, supporting 2024 guidance.EVT
Q3 2024 - Revenue up 2%, but losses deepened and restructuring accelerated in H1 2024.EVT
Q2 2024 - Revenue fell 4% but Biologics grew 10–11%, with guidance and cost savings reaffirmed.EVT
Q1 2025